|
業務類別
|
Biotechnology |
|
業務概覽
|
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol. |
| 公司地址
| 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607 |
| 電話號碼
| +1 844 445-5704 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.xerispharma.com |
| 員工數量
| 435 |
| Mr. John P. Shannon |
Director and Chief Executive Officer |
美元 629.19K |
02/03/2026 |
| Ms. Beth P. Hecht |
Chief Legal Officer and Corporate Secretary |
美元 491.73K |
23/04/2025 |
| Mr. Kevin McCulloch |
President and Chief Operating Officer |
美元 490.35K |
23/04/2025 |
| Dr. Anh Nguyen, M.D. |
Chief Medical Officer |
-- |
24/02/2025 |
| Mr. Steven M. Pieper |
Chief Financial Officer and Principal Accounting officer |
美元 479.58K |
02/03/2026 |
|
|
| Dr. Jeffrey W. Sherman, F.A.C.P.,M.D. |
Independent Director |
02/03/2026 |
| Mr. John H. Johnson |
Independent Director |
02/03/2026 |
| Ms. Marla S. Persky |
Chairperson of the Board |
02/03/2026 |
| Dr. Garheng Kong, M.D.,PhD |
Independent Director |
02/03/2026 |
| Mr. John P. Shannon |
Director and Chief Executive Officer |
02/03/2026 |
| Dr. B. J. Bormann, PhD |
Independent Director |
02/03/2026 |
| Ms. Dawn Halkuff |
Independent Director |
02/03/2026 |
| Mr. James Brady |
Independent Director |
02/03/2026 |
|
|
|
|
